



Press Release

ROVI leads the BioElast Consortium approved in the 2021 Call for Projects in Public-Private Collaboration of the MCIN (AEI)

Madrid: 28 of December 2022

The project entitled “Bioreactors and Biostains with Heparin for the Regeneration of Elastic Tissues (BioElast)”, led by Laboratorios Farmacéuticos ROVI, S.A., in collaboration with the company Regemat 3D, S.L. and the Basque Centre for Macromolecular Design and Engineering Polymat Fundazioa, University of the Basque Country Euskal Herriko Unibertsitatea and Consorcio Centro de Investigación Biomédica in Red M.P. (CIBER, has been funded by MCIN/AEI/10.13039/501100011033 and by the European Union-NextGenerationEU/PRTR, through the call for the 2021 Public-Private Collaboration program (CPP2021-008754).

The objective of the call for grants to public-private partnership projects is to support experimental development in cooperation between companies and research organizations, promoting the development of new technologies, the business application of new ideas and techniques; and contributing to the creation of new products and services. With this, it also seeks to facilitate the transfer of knowledge through actions that eliminate the existing barriers between the different actors in the public and private spheres and increase the dissemination and communication capacities of R+D+i to society by contributing to the fulfilment

of specific objective 5 (SO5) of the State Plan for Scientific, Technical and Innovation Research for the period 2021-2023.



About

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, already present in more than 70 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its enoxaparin biosimilar, developed in-house, in Europe and it is already marketed in 38 countries. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit www.rovi.es. In February 2022, ROVI is still investing in increasing the compounding, aseptic filling, inspection, labelling and packaging capacities at its facilities and expects them to be fully installed at the end of 2024. For more information visit www.rovi.es.